Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Traditional cancer therapy has many disadvantages such as low selectivity and high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance the cytotoxic effect and targeting ability, while reducing the toxicity of antitumor drugs, an antibody drug conjugate (ADC) was developed to deliver small molecular cytotoxic payloads directly to tumor cells by binding to specific antibodies via linkers.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>By reviewing published literature and the current progress of ADCs, we aimed to summarize the basic characteristics, clinical progress, and challenges of ADCs to provide a reference for clinical practice and further research.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>ADC is a conjugate composed of three fundamental components, including monoclonal antibodies, cytotoxic payloads, and stable linkers. The mechanisms of ADC including the classical internalization pathway, antitumor activity of antibodies, bystander effect, and non-internalizing mechanism. With the development of new drugs and advances in technology, various ADCs have achieved clinical efficacy. To date, nine ADCs have received US Food and Drug Administration (FDA) approval in the field of hematologic tumors and solid tumors, which have become routine clinical treatments.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>ADC has changed traditional treatment patterns for cancer patients, which enable the same treatment for pancreatic cancer patients and promote individualized precision treatment. Further exploration of indications could focus on early-stage cancer patients and combined therapy settings. Besides, the mechanisms of drug resistance, manufacturing techniques, optimized treatment regimens, and appropriate patient selection remain the major topics.</p></section>

Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer

DNA Self-Assembly-mediated High Drug-Antibody Ratio ADC Platform for Targeted Tumor Therapy and Imaging

An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions

Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer

Development of antibody-drug conjugates as targeted cancer therapeutics

Drug conjugate-based anticancer therapy - Current status and perspectives

Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)

Biomimetic Nanoerythrosome‐Coated Aptamer–DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐Positive Breast Cancer

The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer

A Narrative Review of Human Epidermal Growth Factor Receptor 2 (Her2)-Targeted Antibody-Drug Conjugates in the Treatment of Breast Cancer

Antibody-drug Conjugates and Their Application in the Treatment of Hematological Malignancies

Targeting cancer with antibody-drug conjugates: Promises and challenges

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Antibody-Drug Conjugates in Breast Cancer: Current Status and Future Directions

A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates

Recent Advances in Antibody-Drug Conjugates for the Treatment of Gastric Cancer